Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nuo Therapeutics Q3 2026 Results: Net Loss of $425K, Loss Narrows

Nuo Therapeutics reported a significant revenue increase to $4.9 million for the nine months ended September 30, 2026, compared to $2.2 million in the prior year, driven by product sales and distribution fees. Despite the growth, the company remains in a stockholders' deficit and continues to rely on debt financing, including $1.175 million in net proceeds from notes payable issued during 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.91.0
Gross profit1.20.6
Net income-0.4-0.5
EPS (diluted, $ a share)$-0.01$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+80.8%
Gross margin63.9%
Operating margin-20.1%
Source

10-Q filed with the SEC, OTC: AURX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nuo Therapeutics, Inc.: key numbers

Share price
$1.09Close, Nov 13
Market cap
$53M
Shares outstanding
48.59MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nuo Therapeutics, Inc.

All →
8:58 AM ET 8-K
Financial Results

Nuo Therapeutics Financial Results

Nuo Therapeutics reported Q3 2026 financial results with total revenue of $1.9 million, an 80% increase year-over-year. The company highlighted strong growth in hospital-based Aurix sales and noted that final 2027 Medicare reimbursement rulings reinforce its long-term growth outlook.

“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above”

David Jorden, Nuo’s Chief Executive and Financial Officer

“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth.”

David Jorden, Nuo’s Chief Executive and Financial Officer
4:58 PM ET 8-K
Loan & Debt

Nuo Therapeutics Debt Financing Update with Scott M. Pittman

Nuo Therapeutics entered into an amendment to its Amended and Restated Loan and Security Agreement to close a second funding tranche of $325,000. The company has now received an aggregate of $2.0 million under the facility, with the new notes bearing 12% interest and maturing on December 31, 2028. The funding involved the joinder of three new lenders and an additional commitment from director Scott M. Pittman.

Counterparty
Scott M. Pittman
Term
through Dec 2028

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.